We Are/Getty Images
VC funding for female-founded startups in Europe is on the rise again, but their share of overall dealmaking is continuing to slide.
According to PitchBook data, startups launched by women raised €10.9 billion (about $12.8 billion) this year, a modest increase from the €10.8 billion raised in 2024. However, this accounts for 17.8% of Europe’s total deal value, compared to 18.5% last year.
Deal count follows a similar trajectory. The number of rounds is lower this year, in line with the broader market, but women founders remain underrepresented in deals compared to 2024.
Raising capital is even more dire for startups with only female founders, which have seen both deal value and count drop. At the current run rate, they are unlikely to break the €1 billion mark for the year, the first time since 2020. The percentage of VC funding for all women-led teams has fallen to its lowest level in nearly a decade, at just 1.2%.
Even in AI, where there’s no shortage of capital, female founders are still capturing a smaller share of the overall market. They were present in only 17.1% of deal count, the lowest share since 2016, and 12.9% of value.
A key factor in the lack of capital going to women founders is the paucity of female GPs in Europe. According to PitchBook’s most recent All In report, only 15% of decision-makers at VC firms with €50 million or more in AUM are women. Just 8.3% of those have a majority of female check writers.
Latest Research
European VC Valuations Report
The largest deal to close this year for a female-founded startup was Maltese crypto exchange Binance‘s $2 billion investment from Abu Dhabi-based tech investor MGX.
Other notable deals included London-based weight loss company Verdiva Bio‘s $411 million Series A led by General Atlantic and Forbion. UK-headquartered AI video startup Synthesia is said to have raised $200 million in a GV-led round, valuing the company at $4 billion.
Recent News
VCs backed the AI boom. Now founders are burying them in slop.
Apollo views daily pricing as key to expanding alternatives access. Industry peers are skeptical.
Learn about our editorial standards.